Optimización del proceso de clarificación en distrito Santo Tomé

Al recibir en concesión los distritos de la AOSC , la Empresa Aguas de Corrientes S.A. debió encarar en la Ciudad de Santo Tomé, ubicada sobre el Río Uruguay, trabajos en la toma, sedimentadores y filtros a presión. En Febrero de 1992 se proyectó la obra Optimización del Clarificador, para modificar el sistema existente por el de: lecho de contacto de sólidos. En octubre del mismo año fueron puestos en servicio los dos sedimentadores obteniendose sustancial mejora en la calidad del agua. El objeto de este trabajo es demostrar; a: disminución de turbiedades, b:variables que fueron necesarias ajustar

Optimización del proceso de clarificación en distrito Santo Tomé

Al recibir en concesión los distritos de la AOSC , la Empresa Aguas de Corrientes S.A. debió encarar en la Ciudad de Santo Tomé, ubicada sobre el Río Uruguay, trabajos en la toma, sedimentadores y filtros a presión. En Febrero de 1992 se proyectó la obra Optimización del Clarificador, para modificar el sistema existente por el de: lecho de contacto de sólidos. En octubre del mismo año fueron puestos en servicio los dos sedimentadores obteniendose sustancial mejora en la calidad del agua. El objeto de este trabajo es demostrar; a: disminución de turbiedades, b:variables que fueron necesarias ajustar

Optimización del proceso de clarificación en distrito Santo Tomé

Expone sobre las obras realizadas con el fin de mejorar la calidad del agua. El objetivo del trabajo es demostrar la disminución de turbiedades y variables que fue necesario ajustar

Optimización del proceso de clarificación en distrilto Santo Tomé

Al recibir en concesión los distritos de la A.O.S.C.la Empresa Aguas de Corrientes S.A. debió encarar en la Ciudad de Santo Tomé, ubicada sobre el Río Uruguay, trabajos en la toma, sedimentadores y filtros a presión. En febrero de 1992 se proyectó la obra:Optimización del clarificador, para modificar el sistema existente por el de Lecho de contacto de sólidos. En octubre del mismo año fueron puestos en servicio los dos sedimentadores obteniendose sustancial mejora en la calidad del agua. El objeto de este trabajo es demostrar: a)Disminución de turbiedades b)Variables que fueron necesarias ajustar

Effects of antioxidant therapy in experimentally induced heart infarcts.

Experiments were performed on dog hearts following coronary ligation and treatment with synthetic antioxidant of dihydroquinoline type. Experimental groups were: control dogs, dogs with ligation of descendens anterior coronary branch, coronary ligated dogs with antioxidant pretreatment and dogs with coronary ligation and simultaneous antioxidant infusion therapy. The heart infarction per se is accompanied by the disintegration of membrane polyunsaturated fatty acids expressed by increase of malondialdehyde (MDA) concentration and the impairment of natural scavenging characterized by the decrease of superoxide dismutase (SOD) and reduced glutathione (GSH) content. The oral pretreatment with antioxidant for 8 days prevented or decreased the unfavourable pathobiochemical responses. The acute infusion therapy exerted no immediate protection, nonetheless, it could decrease the severity of pathological signs.

Inhibition by an antioxidant of the carcinogenic effect of nitrosomorpholine formed in vivo.

In earlier studies, it was found that the new antioxidant, MTDQ-DA ((6,6-methylene-bis)2,2-dimethyl-4-methane-sulphonic acid sodium salt-1,2-dihydroquinoline) (Patent No. 3172) prevented in vivo nitrosation and the acute hepatotoxicity of morpholine plus sodium nitrite in rats. The aim of the present experiments was to examine whether MTDQ-DA could decrease the frequency of tumours induced by simultaneous administration of morpholine and nitrite in the lung adenoma assay. Forty CFLP mice were used in each group and they were killed 8 months after treatment. In group A, treated with 1000 mg/kg morpholine i.g., and in Group B (untreated control) a similar frequency of lung adenomas could be observed (0.13 adenomas/mouse). After the combined i.g. treatment in Group C (MOR, 1000 mg/kg + nitrite, 125 mg/kg), the incidence of lung adenomas was found to be 16.58/mouse. A single dose of MTDQ-DA (500 mg/kg) added to the group C treatment reduced the lung adenoma frequency to 2.47/mouse (Group D). As MTDQ-DA shows neither toxic nor mutagenic effects and inhibits the in vivo nitrosation in both hepatotoxicity and lung adenoma assays, it may be considered to be a potential food additive.

Protective effect of a new antioxidant on acute hepatotoxicity caused by morpholine plus nitrite in rats.

Bis(2,2-dimethyl-4-methane sulphonic acid sodium salt-1,2-dihydroquinoline)-6,6'-methane (MTDQ-DA), a new, non-toxic, water soluble antioxidant, is shown to inhibit liver necrosis induced in rats by N-nitrosomorpholine (N-MOR), itself formed in vivo following the administration simultaneously of morphine (MOR) and sodium nitrite (NaNO2).

Clinical trials with MTDQ /6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)/ an antioxidant with radiation sensitizing effect.

Daily doses of 1320 mg MTDQ have been administered orally to 7 patients for 100 subsequent days. Biological half-life and serum concentration measurements were performed. Function of vital organs, as well as routine laboratory findings revealed that MTDQ did not induce any toxic changes. The effect of MTDQ on the radiosensitivity of hypoxic tumor cells was studied in a combined treatment modality including 12 patients. The action on tumor regression was found encouraging. It has been found remarkable, too, that due to the effect of MTDQ and radiotherapy some of the nonspecific and general symptoms (e. g. pruritus) also disappeared.

[Study of the biochemical and radiochemical effects of the agent MTDQ (author's transl]. / Beitrag zu den bio- und radiochemischen Wirkungen der Verbindung MTDQ.

The antioxidant MTDQ exhibits a radiosensitizing effect and was used in pretreatment of radiation-resistant human tumors, e.g. synoviomas, sarcomas, von Recklinghausen disease. After this premedication and fractionated radiation therapy of different kinds a permanent regression of the tumors was observed. The radiosensitizing compound is non-toxic and selectively accumulates in tumorous tissues. The chemical structure (three functional groups) and in vitro tests make probable that the main factors in the mechanism of action are peroxide decomposition, hydrol formation, polymerization and, in the course of those reactions, the in situ release of oxygen.

Biopharmacological investigation of 6,6'methylene-bis/2,2,4-trimethyl-1,2-dihydroquinoline (MTDQ) a radical binding antioxidant of secondary amine type.

The evidence of free radicals in tumor tissue and the possibility of their experimental influencing by means of antioxidants justifies the search for new pharmacological groups of tumor inhibiting agents. The authors synthesized a sterically inhibited, heterocyclic, bifunctional, non-toxic radical binding antioxidant of secondary amine type. The structural change is interpreted with the possibility of recombination characteristic for secondary amine groups and the double chain closing effect. The conjugation effect secures mobility of the hydrogen atom. The compound contains 10 to 12 per cent dimer-trimer of higher biological activity than monomers, due to higher molecular weight. An additional pharmacodynamic advantage compared to hitherto known antioxidants consists in its lower vapour volutility and the biradicality.

[Investigation on radiosensitizing and tumor inhibiting actions of the antioxidant MTDQ (6,6'-methylen-bis/2,2,4-trimethyl-1-1,2-dihydroquinolin) (author's transl)]. / Untersuchung der radiosensibilisierenden und tumorhemmenden Wirkung des als MTDQ (6,6' methylen bis/2,2,4-trimethyl-1,2-dihydroquinolin) bezeichneten antioxidans

Unlike the hitherto known antioxidants, MTDQ is not a radiation protective-but a radiation sensitizing agent. According to autoradiographic findings accumulation of 14C-labelled MTDQ occurs in tumor tissue. The compound was found to be suitable in the combined treatment (MTDQ and 300 R x-ray therapy). In these instances tumor weight of solid Ehrlich- and Yoshida-tumors will be reduced even by doses ineffective as monotherapy. The MTDQ pretreatment of NKLy ascites tumorbearing rats raised survival rat by 60 to 90 per cent (controls 20%) and inhibited growth of solid Yoshida-tumors. No side-effects have been observed. In contrast to other antineoplastic agents MTDQ does not induce granulocytopenia.